— Diebold Nixdorf (NYSE: DBD) reported its fourth-quarter 2019 adjusted earnings of $0.47 per share versus $0.50 per share expected.
— Total net sales declined by 11% to $1.15 billion versus $1.16 billion expected. The results were impacted by divestitures and other deliberate actions to improve the quality of revenue.
— Sales from Eurasia Banking dropped by 13% and that from the Americas Banking declined by 3%. Total retail sales fell by 18%.
— Looking ahead into the full year 2020, the company expects its total revenue in the range of $4.2-4.3 billion. The consensus estimates revenue of $4.27 billion.
— Adjusted EBITDA is expected to be in the range of $430-470 million and net cash provided by operating activities is predicted to be in the $170-200 million range for the full year.
— Capital expenditures are anticipated to be about $70 million while free cash flow is projected to be $100-130 million for the full year 2020.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
